Ajay Major, Founder and President of Pager Publications and Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X:
“PIV vs CVC 1L anthracycline chemo –
- 1414 patients: 50% CVC (79% port, 22% PICC) – extravasation: 1 CVC, 2 PIV
- No difference in induration, phlebitis, VTE, erythema between CVC and PIV
- However, more pain/tenderness and infiltration with PIV
Which centers use PIV for R-CHOP/ABVD?”
Andrew Evens, Deputy Director for Clinical Services at Rutgers Cancer Institute, shared this post, adding:
“>1,400 lymphoma patients and >9,300 anthracycline treatment infusions (with ABVD or CHOP) were examined (~50% each peripheral IV [PIV] and central port/PICC): there was 1 confirmed case of extravasation (1 of 4363 [0.02%] infusions) for patients treated via PIV.
Altogether, use of PIV is safe and effective for lymphoma pts treated with anthracycline-based regimens.
Kudos to Yun Kyoung Ryu for leading this large multicenter project and analysis.”
More posts from ASH 2025.
